Filtered By:
Condition: Stroke
Drug: Botox
Countries: Italy Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey.
Authors: Sandrini G, Baricich A, Cisari C, Paolucci S, Smania N, Picelli A Abstract The present paper provides practical guidance on the management of adult spasticity with OnabotulinumtoxinA. Advisory Board members reviewed the available evidence and discussed their personal experiences in order to address the unmet needs in the management of spasticity with botulinum toxin type A identified by the recent Italian Real-Life Post-Stroke Spasticity Survey. Stroke patients should be referred to spasticity services that have adequate facilities and multidisciplinary teams with the necessary training, competence and exp...
Source: Functional Neurology - April 12, 2018 Category: Neurology Tags: Funct Neurol Source Type: research

The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A.
Authors: Picelli A, Baricich A, Cisari C, Paolucci S, Smania N, Sandrini G Abstract The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about "real-life" post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 54...
Source: Functional Neurology - July 7, 2017 Category: Neurology Tags: Funct Neurol Source Type: research